Company Overview - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk and retinal diseases [3] - BioAge is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs that leverage insights from human longevity data [3] Upcoming Events - BioAge will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [1] - CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat and one-on-one meetings during the conference [2] - A live webcast of the presentation will be available, with replays accessible on the company's investor website for 30 days post-event [2] Clinical Development - A Phase 1 SAD/MAD trial of BGE-102 is currently underway, with topline data, including additional MAD cohorts, expected in the first half of 2026 [3]
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference